Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.

Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, Tüting T.

Nature. 2012 Oct 18;490(7420):412-6. doi: 10.1038/nature11538. Epub 2012 Oct 10.

PMID:
23051752
[PubMed - indexed for MEDLINE]
2.

Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.

Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE, Rosenberg SA.

J Immunol. 1996 Jan 15;156(2):700-10.

PMID:
8543823
[PubMed - indexed for MEDLINE]
3.

Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.

Slingluff CL Jr, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C, Harthun NL, Huczko EL, Hunt DF, Darrow TL, Engelhard VH.

Cancer Immunol Immunother. 2000 Mar;48(12):661-72.

PMID:
10752474
[PubMed - indexed for MEDLINE]
4.

Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.

Sutmuller RP, Schurmans LR, van Duivenvoorde LM, Tine JA, van Der Voort EI, Toes RE, Melief CJ, Jager MJ, Offringa R.

J Immunol. 2000 Dec 15;165(12):7308-15.

PMID:
11120866
[PubMed - indexed for MEDLINE]
Free Article
5.

T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.

Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA.

Cancer J. 2000 Mar-Apr;6(2):69-77.

PMID:
11069222
[PubMed - indexed for MEDLINE]
7.

Cancer therapy: Tumours switch to resist.

Ribas A, Tumeh PC.

Nature. 2012 Oct 18;490(7420):347-8. doi: 10.1038/nature11489. Epub 2012 Oct 10. No abstract available.

PMID:
23051745
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens.

Kirkin AF, thor Straten P, Zeuthen J.

Cancer Immunol Immunother. 1996 May;42(4):203-12.

PMID:
8665567
[PubMed - indexed for MEDLINE]
9.

Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.

Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA.

Cancer Res. 1995 Nov 1;55(21):4972-9.

PMID:
7585538
[PubMed - indexed for MEDLINE]
Free Article
10.

Autonomous histopathological regression of primary tumours associated with specific immune responses to cancer antigens.

Saleh FH, Crotty KA, Hersey P, Menzies SW, Rahman W.

J Pathol. 2003 Jul;200(3):383-95. Retraction in: J Pathol. 2006 Nov;210(3):383.

PMID:
12845635
[PubMed - indexed for MEDLINE]
11.

Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.

Kohlmeyer J, Cron M, Landsberg J, Bald T, Renn M, Mikus S, Bondong S, Wikasari D, Gaffal E, Hartmann G, Tüting T.

Cancer Res. 2009 Aug 1;69(15):6265-74. doi: 10.1158/0008-5472.CAN-09-0579. Epub 2009 Jul 21.

PMID:
19622767
[PubMed - indexed for MEDLINE]
Free Article
12.

Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?

Auphan-Anezin N, Verdeil G, Grange M, Soudja SM, Wehbe M, Buferne M, Mas A, Schmitt-Verhulst AM.

Pigment Cell Melanoma Res. 2013 Mar;26(2):167-75. doi: 10.1111/pcmr.12056. Epub 2012 Dec 27.

PMID:
23217139
[PubMed - indexed for MEDLINE]
13.

Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.

Ye Z, Shi M, Chan T, Sas S, Xu S, Xiang J.

Cancer Gene Ther. 2007 Jul;14(7):661-75. Epub 2007 May 4.

PMID:
17479109
[PubMed - indexed for MEDLINE]
14.

Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells.

Singh V, Ji Q, Feigenbaum L, Leighty RM, Hurwitz AA.

J Immunother. 2009 Feb-Mar;32(2):129-39. doi: 10.1097/CJI.0b013e31819144d7.

PMID:
19238011
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.

Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.

J Immunol. 2002 Apr 1;168(7):3484-92.

PMID:
11907109
[PubMed - indexed for MEDLINE]
Free Article
16.

Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.

Lozupone F, Rivoltini L, Luciani F, Venditti M, Lugini L, Cova A, Squarcina P, Parmiani G, Belardelli F, Fais S.

Eur J Immunol. 2003 Feb;33(2):556-66.

PMID:
12645955
[PubMed - indexed for MEDLINE]
17.

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG.

Cancer Res. 2011 Feb 15;71(4):1253-62. doi: 10.1158/0008-5472.CAN-10-2693. Epub 2011 Jan 7.

PMID:
21216894
[PubMed - indexed for MEDLINE]
Free Article
18.

T-cell receptor gene therapy of established tumors in a murine melanoma model.

Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA.

J Immunother. 2008 Jan;31(1):1-6.

PMID:
18157006
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A.

Cancer Res. 2003 May 15;63(10):2535-45.

PMID:
12750277
[PubMed - indexed for MEDLINE]
Free Article
20.

Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.

Milling SW, Sai T, Silvers WK, Mintz B.

Melanoma Res. 2004 Dec;14(6):555-62.

PMID:
15577330
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk